Summary

Pigmentation Disorder Treatment Market – Scope of Report
TMR’s report on the global pigmentation disorder treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global pigmentation disorder treatment market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global pigmentation disorder treatment market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the pigmentation disorder treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global pigmentation disorder treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global pigmentation disorder treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global pigmentation disorder treatment market.

The report delves into the competitive landscape of the global pigmentation disorder treatment market. Key players operating in the global pigmentation disorder treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global pigmentation disorder treatment market profiled in this report.

Key Questions Answered in Global pigmentation disorder treatment Market Report
• What is the sales/revenue generated by pigmentation disorder treatment across all regions during the forecast period?
• What are the opportunities in the global pigmentation disorder treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Pigmentation Disorder Treatment Market – Research Objectives and Research Approach
The comprehensive report on the global pigmentation disorder treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global pigmentation disorder treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global pigmentation disorder treatment market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pigmentation Disorder Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pigmentation Disorder Treatment Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Pigmentation Disorder Treatment Market Analysis and Forecast, by Treatment
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment, 2017–2031
6.3.1. Topical Drugs
6.3.2. Laser Therapy
6.3.3. Chemical Peels
6.3.4. Microdermabrasion
6.3.5. Phototherapy
6.3.6. Others
6.4. Market Attractiveness Analysis, by Treatment
7. Global Pigmentation Disorder Treatment Market Analysis and Forecast, by Disease Indication
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Indication, 2017–2031
7.3.1. Hypopigmentation
7.3.1.1. Vitiligo
7.3.1.2. Albinism
7.3.1.3. Others
7.3.2. Hyperpigmentation
7.3.2.1. Melasma
7.3.2.2. Post-inflammatory Hyperpigmentation
7.3.2.3. Solar Lentigines
7.3.2.4. Others
7.4. Market Attractiveness Analysis, by Disease Indication
8. Global Pigmentation Disorder Treatment Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Aesthetic Clinics & Dermatology Centers
8.3.3. Others
8.4. Market Attractiveness Analysis, by Disease Indication
9. Global Pigmentation Disorder Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Pigmentation Disorder Treatment Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Treatment, 2017–2031
10.3.1. Topical Drugs
10.3.2. Laser Therapy
10.3.3. Chemical Peels
10.3.4. Microdermabrasion
10.3.5. Phototherapy
10.3.6. Others
10.4. Market Value Forecast, by Disease Indication, 2017–2031
10.4.1. Hypopigmentation
10.4.1.1. Vitiligo
10.4.1.2. Albinism
10.4.1.3. Others
10.4.2. Hyperpigmentation
10.5. Melasma
10.5.1. Post-inflammatory Hyperpigmentation
10.5.2. Solar Lentigines
10.5.3. Others
10.6. Market Value Forecast, by End-user, 2017–2031
10.6.1. Hospitals
10.6.2. Aesthetic Clinics & Dermatology Centers
10.6.3. Others
10.7. Market Value Forecast, by Country, 2017–2031
10.7.1. U.S.
10.7.2. Canada
10.8. Market Attractiveness Analysis
10.8.1. By Treatment
10.8.2. By Disease Indication
10.8.3. By End-user
10.8.4. By Country
11. Europe Pigmentation Disorder Treatment Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Treatment, 2017–2031
11.3.1. Topical Drugs
11.3.2. Laser Therapy
11.3.3. Chemical Peels
11.3.4. Microdermabrasion
11.3.5. Phototherapy
11.3.6. Others
11.4. Market Value Forecast, by Disease Indication, 2017–2031
11.4.1. Hypopigmentation
11.4.1.1. Vitiligo
11.4.1.2. Albinism
11.4.1.3. Others
11.4.2. Hyperpigmentation
11.4.2.1. Melasma
11.4.2.2. Post-inflammatory Hyperpigmentation
11.4.2.3. Solar Lentigines
11.4.2.4. Others
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospitals
11.5.2. Aesthetic Clinics & Dermatology Centers
11.5.3. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Treatment
11.7.2. By Disease Indication
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Pigmentation Disorder Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Treatment, 2017–2031
12.3.1. Topical Drugs
12.3.2. Laser Therapy
12.3.3. Chemical Peels
12.3.4. Microdermabrasion
12.3.5. Phototherapy
12.3.6. Others
12.4. Market Value Forecast, by Disease Indication, 2017–2031
12.4.1. Hypopigmentation
12.4.1.1. Vitiligo
12.4.1.2. Albinism
12.4.1.3. Others
12.4.2. Hyperpigmentation
12.4.2.1. Melasma
12.4.2.2. Post-inflammatory Hyperpigmentation
12.4.2.3. Solar Lentigines
12.4.2.4. Others
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospitals
12.5.2. Aesthetic Clinics & Dermatology Centers
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Treatment
12.7.2. By Disease Indication
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Pigmentation Disorder Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Treatment, 2017–2031
13.3.1. Topical Drugs
13.3.2. Laser Therapy
13.3.3. Chemical Peels
13.3.4. Microdermabrasion
13.3.5. Phototherapy
13.3.6. Others
13.4. Market Value Forecast, by Disease Indication, 2017–2031
13.4.1. Hypopigmentation
13.4.1.1. Vitiligo
13.4.1.2. Albinism
13.4.1.3. Others
13.4.2. Hyperpigmentation
13.4.2.1. Melasma
13.4.2.2. Post-inflammatory Hyperpigmentation
13.4.2.3. Solar Lentigines
13.5. Others
13.6. Market Value Forecast, by End-user, 2017–2031
13.6.1. Hospitals
13.6.2. Aesthetic Clinics & Dermatology Centers
13.6.3. Others
13.7. Market Value Forecast, by Country/Sub-region, 2017–2031
13.7.1. Brazil
13.7.2. Mexico
13.7.3. Rest of Latin America
13.8. Market Attractiveness Analysis
13.8.1. By Treatment
13.8.2. By Disease Indication
13.8.3. By End-user
13.8.4. By Country/Sub-region
14. Middle East & Africa Pigmentation Disorder Treatment Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Treatment, 2017–2031
14.3.1. Topical Drugs
14.3.2. Laser Therapy
14.3.3. Chemical Peels
14.3.4. Microdermabrasion
14.3.5. Phototherapy
14.3.6. Others
14.4. Market Value Forecast, by Disease Indication, 2017–2031
14.4.1. Hypopigmentation
14.4.1.1. Vitiligo
14.4.1.2. Albinism
14.4.1.3. Others
14.4.2. Hyperpigmentation
14.4.2.1. Melasma
14.4.2.2. Post-inflammatory Hyperpigmentation
14.4.2.3. Solar Lentigines
14.4.2.4. Others
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospitals
14.5.2. Aesthetic Clinics & Dermatology Centers
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Treatment
14.7.2. By Disease Indication
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Bayer AG
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Galderma S.A. (Nestle Skin Health S.A)
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. SkinCeuticals
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Pierre Fabre
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. EpiPharm AG
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. RXi Pharmaceuticals Corporation
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Obagi Cosmeceuticals LLC (Obagi Medical)
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Vivier Pharma
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview